.Home
.Publications
.Resources
.Link Codes
.About Us
.eNewsletter
Clinical Trials
May/June 2003
Sub Nav
Clinical Trials
Detailed Oncology Clinical Trials
Code: o43623
Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma
Code: o43622
Radiotherapy Combined With Temozolomide vs Carmustine in Patients With Anaplastic Astrocytoma
Code: o43620
Weekly Taxol and Bryostatin-1 in Hormone-Refractory Prostate Cancer
Code: o43621
Phase III Study to Compare the Overall Survival and Safety of Biweekly Intratumoral Administration of INGN 201 vs Weekly Methotrexate in Subjects With Refractory Squamous Cell Carcinoma of the Head and Neck
Code: o43617
Study of IV Busulfan Combined with 12 cGy of Fractionated Total Body Irradiation and Etoposide as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies
Code: o43618
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
Code: o43619
Trial Assessing the Safety and Efficacy of Thalidomide for the Treatment Of Anemia in Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes
Code: o43614
Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Stage I or IIA Breast Cancer
Code: o43615
Radiotherapy and Cisplatin With or Without Epoetin Alfa in Patients With Cervical Cancer and Anemia
Code: o43616
RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Refractory Lymphomas
Code: o43611
Neoadjuvant and Concurrent Temozolomide With Radiotherapy in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
Code: o43612
Novel Epothilone BMS-247550 in Patients With Small Cell Lung Cancer Refractory to First-Line Chemotherapy
Code: o43613
Pemetrexed Plus Gemcitabine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Code: o4368
Gemcitabine, Taxotere, and Xeloda Combination Chemotherapy in Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
Code: o4369
Intravenous BCX-1777 in Patients With Refractory T-Cell or Non T-Cell Hematologic Malignancies
Code: o43610
Mylotarg Plus Cytarabine and Daunorubicin in Relapsed/Refractory Patients With Acute Myeloid Leukemia, and in Younger De Novo Patients With AML
Code: o4365
CpG 7909 in Patients With Stage IV Renal Cell Cancer
Code: o4366
Docetaxel in Women With Metastatic Breast Cancer
Code: o4367
Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven) in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
Code: o4362
Biochemically Synergistic Regimen for Advanced Pancreatic Cancer: Gemcitabine-Docetaxel-Capecitabine
Code: o4363
Calcitriol in Transfusion-Dependent Myelodysplastic Syndrome Patients
Code: o4364
Cisplatin, Gemcitabine, and Gefitinib in Patients With Metastatic Transitional Cell Carcinoma of the Urothelium
Code: o4361
Adjuvant Chemoradiation After Resection in Patients With Gastric or Gastroesophageal Adenocarcinoma
Departments
Cover Story
Technology 101
News Watch
Personal Finance
Feature Story
Physician's Fourm
Clinician's Corner
PDA Resources
Internet Listings
Upcoming Events
Clinical Trials
eAbstracts
CME Center
Medical Websites
Patient Friendly
Privacy
Site Map
Contact